Scholastic (NASDAQ:SCHL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops

Scholastic (NASDAQ: SCHL) reported Q2 CY2026 revenue of $476.1 million, down 6.3% year on year and below analyst estimates. Non-GAAP EPS was $2.19, about 1.4% above consensus. The company said adjusted EBITDA rose in line with guidance, but full-year EBITDA guidance missed. Shares fell 6.6% to $43.37 after the release.

Original reporting
Published Jul 23, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Scholastic (NASDAQ:SCHL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops — source image
Decision brief

The 30-second read

$SCHLBearishMed
01

Why it matters

The key tradable issue is the combination of a Q2 revenue decline that missed estimates and a full-year EBITDA guidance miss, despite non-GAAP EPS being slightly above consensus and adjusted EBITDA meeting guidance.

02

Market read

Investors are likely repricing near-term revenue expectations and the credibility of full-year EBITDA guidance, which can affect valuation multiples for the stock.

03

What to watch

The article notes ongoing multi-year transformation and stable operating margin; if investors focus on cost discipline and balance-sheet progress, the selloff could be partially mean-reverting.

Relevance 7/10Novelty 7/10Timing: after-hours reaction to Q2 CY2026 results and guidance commentary

Background

Scholastic is an educational publishing and media company, including the Scholastic Book Fair, and is in a multi-year transformation aimed at improving governance, organization, strategy, and balance sheet.

Company-level read

Ticker impact

$SCHLBearishMedium confidence
Context

Scholastic reported Q2 CY2026 revenue of $476.1M, down 6.3% YoY, missing Wall Street estimates and sending the stock down 6.6% to $43.37.

Expected impact

Near-term bias remains negative until investors get clarity on revenue trajectory and full-year EBITDA guidance.

Evidence & confidence

The article provides concrete Q2 revenue and margin datapoints plus a stated full-year EBITDA guidance miss, which typically drives expectation resets even if EPS/EBITDA beat on a narrow basis.

Market effects

Signals continued demand softness in children’s education publishing, with investors likely scrutinizing revenue durability versus cost/margin stability.

No specific regional impact described beyond US-listed equity reaction.

Limited, as the article focuses on company-specific quarterly results and guidance.

Counterpoint

Non-GAAP EPS beat and adjusted EBITDA rose in line with guidance, suggesting the market may be over-penalizing a single-quarter revenue softness.

Key entities

  • Scholastic

    Reported Q2 CY2026 revenue of $476.1M (down 6.3% YoY) and non-GAAP EPS of $2.19, with the stock down 6.6% after results.

  • Peter Warwick

    CEO who said fiscal 2026 showed earnings power and that adjusted EBITDA rose in line with guidance.

Related articles

$SCHLMed

Scholastic Corporation Q4 2026 Earnings Call Summary

Scholastic (Scholastic Corporation) reported a 32% rise in adjusted operating income attributed to a multiyear efficiency and integrated publishing and school growth transformation. Management said Book Fairs growth was driven by higher fair counts and digital tools. Fiscal 2027 guidance calls for 2% to 4% revenue growth and higher adjusted EBITDA, with capital returns supported by sale-leasebacks and leverage targets of 2x to 2.5x.

$SCHLMed

SCHOLASTIC CORP (SCHL): Results of Operations and Financial Condition

SCHOLASTIC CORP (SCHL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fy26q4pressrelease.htm EX-99.1 Document Scholastic Reports Fourth Quarter and Fiscal 2026 Results Fiscal 2026 Operating Income of $15.2 Million; Adjusted EBITDA of $151.5 Million, Up 4%, in Line With Guidance Returned Over $285 Million to Shareholders During Fiscal Year

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.